We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
- Authors
Younes, Anas; Gopal, Ajay K; Smith, Scott E; Ansell, Stephen M; Rosenblatt, Joseph D; Savage, Kerry J; Ramchandren, Radhakrishnan; Bartlett, Nancy L; Cheson, Bruce D; de Vos, Sven; Forero-Torres, Andres; Moskowitz, Craig H; Connors, Joseph M; Engert, Andreas; Larsen, Emily K; Kennedy, Dana A; Sievers, Eric L; Chen, Robert
- Abstract
Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing cells. In phase I studies, brentuximab vedotin demonstrated significant activity with a favorable safety profile in patients with relapsed or refractory CD30-positive lymphomas.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Vol 30, Issue 18, p2183
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2011.38.0410